Glucose Management Practice Test

These questions are part of the practice quiz. Start practicing

• Where is insulin produced?
• How are alpha-glucosidase inhibitors administered?
• Which criterion is used in the oral glucose tolerance test for diagnosing diabetes?
• Which of the following is NOT a listed long-acting insulin analog?
• Which of the following are drug interactions with canagliflozin?
• What is the first-line agent in the described type 2 diabetes treatment plan?
• Which is a mechanism of action of metformin?
• Which statement about postprandial glucose and A1C is correct?
• Which of the following is a GLP-1 receptor agonist?
• In DKA fluid therapy, when is it appropriate to switch from 0.9% NaCl to 0.45% NaCl?
• Which statement about CGM accuracy is true regarding MARD?
• What is the recommended approach to starting metformin in patients with reduced kidney function?
• In DKA, when should insulin be withheld due to potassium level, and when should potassium be replaced?
• Which adverse event is listed for new GLP-1 receptor agonists?
• In DKA management, when the potassium level is 3.3–5.0 mEq/L, what is recommended?
• Using the 500-rule, how is the insulin-to-carbohydrate ratio (ICR) derived?
• Adjustments for glycemic targets in older adults?
• What is recommended if metformin fails or is contraindicated?
• What is the recommended monitoring for lipolysis and ketone production in DKA?
• Which approach helps distinguish postprandial hyperglycemia from fasting hyperglycemia when adjusting therapy?
• Which sign is commonly observed in diabetic ketoacidosis?
• Which statement about DPP-4 inhibitors is true?
• Can long-acting insulin be mixed with other forms in the same syringe?
• Alpha-glucosidase inhibitors can decrease the absorption of which nutrient?
• Which of the following is a GLP-1 receptor agonist used for type 2 diabetes and weight loss?
• Which agents are described as new GLP-1 receptor agonists for type 2 diabetes or weight loss?
• Which test reflects average blood glucose over roughly three months?
• Which statement best describes the relationship between postprandial glucose and A1C?
• Which statement best describes the sequence of therapy for type 2 diabetes as described here?
• How often should A1c be checked in diabetes management?
• Which sites are listed for subcutaneous insulin administration?
• Lipohypertrophy is most likely caused by which practice?
• Which DPP-4 inhibitor is listed with the brand name Januvia?
• Which statement best describes the administration timing of repaglinide?
• How should severe hypoglycemia with impaired consciousness be treated?
• What is the typical starting dose and monitoring for a patient on continuous insulin infusion in DKA?
• Which of the following is a long-acting insulin analog?
• Which order is correct when administering intermediate and regular insulin together?
• Which of the following are common insulin-related complications?
• Colesevelam is which type of lipid-lowering agent?
• Which of the following describes common adverse effects of alpha-glucosidase inhibitors?
• What does the MARD value indicate in CGM readings?
• In the management of Hyperosmolar Hyperglycemic State, what is the role of hydration status and initial fluid choice?
• If a CGM shows a rapid decline into hypoglycemia and the patient is symptomatic, what is the recommended action?
• If potassium is normal or high and hyperglycemia persists after initial fluids in DKA, what is the recommended step?
• What are common triggers for DKA in patients with type 1 diabetes?
• What is the initial insulin infusion rate after fluids are started?
• Which drug is primarily eliminated by the liver?
• Exenatide is a GLP-1 receptor agonist.
• Why are SGLT2 inhibitors associated with euglycemic diabetic ketoacidosis?
• What effect do nonselective beta-blockers have on hypoglycemia recognition?
• Metformin can decrease absorption of which vitamins?
• Which adverse effect is associated with thiazolidinedione therapy?
• To manage postprandial hyperglycemia in type 2 diabetes with standard basal insulin, which approach is recommended?
• Fast-acting insulin formulations are?
• The glucose management goal in diabetes care is
• What is the correction factor per 1 unit insulin according to the 1800-rule?
• Do sulfonylureas cause hypoglycemia?
• In pediatric patients, what is the most common complication in diabetes?
• Which class of drugs reduces insulin resistance?
• What is a common injection-site complication of insulin therapy?
• When is the best time to take a sulfonylurea?
• Sulfonylureas should be avoided in which situation?
• In DKA management, when should dextrose be added to IV fluids?
• Which condition increases the risk of developing euglycemic DKA in patients taking SGLT2 inhibitors?
• Which of the following items are common presenting features of diabetic ketoacidosis?
• How do you correct sodium for hyperglycemia in DKA/HHS?
• DPP-4 inhibitors have no relevant drug-drug interactions or contraindications.
• What is the first-line fluid in diabetic ketoacidosis and how is it administered?
• Meglitinides are shorter acting than sulfonylureas.
• Which adverse effect is associated with amylin mimetics?
• Which are common adverse effects of metformin?
• What is the typical preprandial plasma glucose target for most nonpregnant adults with diabetes?
• Which option lists a GLP-1 receptor agonist?
• Long-acting insulin is primarily used for basal control. Which option reflects this use most accurately?
• Which of the following is a sign of impending insulin pump failure?
• Which mechanism reduces hepatic glucose production?
• Which statement is true about drawing regular insulin with intermediate insulin?
• In diabetic ketoacidosis, bicarbonate therapy is recommended under what condition?
• Which statement about meglitinides is true?
• When should you switch to dextrose-containing fluids during DKA treatment?
• Duration of fast-acting insulin?
• Which statement about GLP-1 receptor agonists is NOT supported by the material?
• Which of the following interactions increases the risk of hypoglycemia when taking sulfonylureas?
• What is a fatal consequence of hypoglycemia?
• Which site provides the most consistent absorption for insulin?
• What factors increase insulin requirements during an acute illness?
• Which insulin is categorized as intermediate-acting?
• Which features distinguish hyperosmolar hyperglycemic state (HHS) from diabetic ketoacidosis?
• In DKA, fluid management as glucose falls?
• During a sick day for type 1 diabetes when meals cannot be tolerated, what is the recommended insulin approach?
• How is euglycemic diabetic ketoacidosis defined?
• Which drugs are sulfonylureas?
• Which mechanism is described as improving insulin sensitivity?
• During illness, what is the purpose of continuing basal insulin in type 1 diabetes?
• What are the typical glucose targets during pregnancy for a patient with diabetes?
• Which of the following is an SGLT-2 inhibitor?
• What is the general in-hospital glucose target range for non-critically ill patients?
• What is the purpose of corrections around meals in postprandial management?
• Which of the following is NOT a DPP-4 inhibitor?
• What is the mechanism of action of meglitinides (glinides)?
• Which of the following is a common symptom of hypoglycemia that prompts immediate treatment?
• Which insulin is not rapid-acting?
• What strategy helps mitigate hyperglycemia risk when steroids are used in a patient with diabetes?
• MOA of amylin mimetics like pramlintide?
• Regular insulin MOA?
• What is glycemic variability and why is it clinically important?
• What are some critical components of a comprehensive glucose management plan for hospitalized patients?
• Which mechanism replaces insulin?
• Which of the following represents main categories of antidiabetic medications that do not directly modify insulin therapy?
• At what point should you switch to dextrose-containing fluids in DKA management?
• Which drug is a meglitinide?
• What is the primary mechanism of action of thiazolidinediones?
• Which of the following is NOT a route for regular insulin formulations?
• HHS occurs more commonly in which type of diabetes?
• In DKA management with IV insulin, how often should blood glucose be checked?
• Which is a common adverse effect of sulfonylureas?
• Which storage condition helps insulin stability?
• Opened insulin lasts for how long?
• Nateglinide peak occurs around how many minutes after dosing?
• Pramlintide is an amylin mimetic used with insulin in which diabetes types?
• Which is a component of DKA treatment?
• Bromocriptine is classified as which type of medication?
• Which item best represents a core component of a hospital glucose management protocol?
• Which substances interact with metformin?
• Which statement about metformin and hypoglycemia is correct?
• Which statement best describes the rationale for hydration during sick day management?
• Where should unopened insulin be stored?
• What is the primary mechanism of action of DPP-4 inhibitors?
• What are potential adverse effects of DPP-4 inhibitors?
• A fasting glucose greater than 126 mg/dL is diagnostic for diabetes.
• Which scenarios are commonly associated with euglycemic DKA?
• When is fast-acting glucose taken?
• Which drug is an amylin mimetic that complements insulin?
• First-line pharmacotherapy for type 2 diabetes is
• Repaglinide peak concentration occurs approximately after how long?
• Peak and duration of regular insulin?
• Sulfonylurea MOA?
• Which injection site is associated with the slowest absorption for insulin?
• The Dawn phenomenon is best described as early morning hyperglycemia due to dawn hormones. What is a common management approach?
• The statement 'In Hyperosmolar Hyperglycemic State, there is little to no change in blood pH or ketoacid levels' is true or false?
• What is the typical administration frequency of intermediate insulin for glycemic control?
• A1c range defines prediabetes?
• An A1c of 5.9% indicates prediabetes.
• What is the typical A1C goal for many adults with diabetes?
• DKA signs beyond hyperglycemia?
• How is the anion gap calculated, and what does elevated gap indicate in DKA?
• The OGTT criterion for diabetes is a 2-hour plasma glucose greater than 200 mg/dL.
• What is the mechanism of action of alpha-glucosidase inhibitors?
• When is a switch to a basal-bolus regimen appropriate for type 2 diabetes?
• SGLT-2 inhibitors work by increasing urinary glucose excretion.
• Which drugs are DPP-4 inhibitors?
• Which of the following is a symptom of hypoglycemia?
• Which mechanism mimics incretin hormones?
• What defines euglycemic diabetic ketoacidosis (DKA)?
• How should exercise be managed for a person with type 1 diabetes on insulin therapy?
• Which drug is a DPP-4 inhibitor?
• Repaglinide is primarily eliminated by which organ?
• Are alpha-glucosidase inhibitors approved only for type 2 diabetes mellitus?
• Which insulin is a short-acting/regular insulin?
• A1c goal for most diabetes patients is
• Which mechanism increases glucose secretion in urine?
• How does dehydration affect glucose concentration readings and management?
• How often should blood glucose be checked after starting IV insulin in DKA?
• How does pregnancy affect insulin requirements?
• What is the mechanism of GLP-1 receptor agonists?
• Why is interstitial CGM measurement lagged, and how should this affect treatment decisions?
• Why is rapid-acting insulin preferred for correcting hyperglycemia?
• What is the typical route for administering long-acting insulin?
• Which statement best describes the dehydration aspect of diabetic ketoacidosis?
• Common adverse effects of SGLT-2 inhibitors include genital fungal infections and increased urination.
• Which pump-related issue can manifest as signs of impending pump failure?
• What does the term ICR stand for in insulin therapy?
• Which agent is a dual GIP and GLP-1 receptor agonist?
• How does glucagon work in severe hypoglycemia, and what follow-up steps are needed?
• Pre-diabetes is an ______.
• In a multiple daily injections regimen, what is the primary role of basal insulin versus prandial insulin?
• The major cause of complications and death in diabetes is due to which type of vascular damage?
• To address postprandial hyperglycemia in type 2 diabetes when using basal insulin, which adjustment is commonly considered?
• Do alpha-glucosidase inhibitors carry a risk of hypoglycemia when used as monotherapy?
• Which CGM metric is best used to assess time within target range, and what is a typical target?
• Which mechanism delays carbohydrate absorption?
• DPP-4 inhibitors are commonly referred to by which suffix?
• Which insulin type is used with the 1800-rule correction factor?
• Which fasting glucose range defines prediabetes?
• Which of the following is a typical appearance of intermediate-acting insulin?
• DPP-4 inhibitors have a dual effect on insulin and glucagon release. Which description is correct?
• When to take regular insulin?
• Which insulin type is typically cloudy in appearance?
• Amylin mimetics have what impact on the absorption of oral medications?
• In DKA management, bicarbonate therapy is not routinely recommended unless the pH is below which threshold?
• Which metformin formulation is dosed twice daily with meals?
• Which factor is used to guide insulin-to-carbohydrate ratio (ICR) adjustment after the initial 500-rule estimate?
• How should clinicians use CGM data when readings are abnormal?
• What is added after metformin failure in the described plan?